Leukemia

Overview

Leukemia is not one disease but a family of hematologic malignancies in which abnormal precursor or mature blood cells proliferate in the bone marrow, blood and sometimes other tissues. Classification depends on cell lineage, degree of maturation, genetic features and whether the clinical course is acute or chronic. ^{[1] [2]}

Leukemic clones acquire genetic or chromosomal changes that disrupt normal control of cell growth, maturation and survival. As abnormal cells accumulate, they can crowd out normal red-cell, platelet and white-cell production, producing anemia, bleeding and infection risk. Specific molecular lesions also define diseases and create therapeutic targets—for example BCR::ABL1 in CML. ^{[1] [2]}

Acute leukemias can cause symptoms over days to weeks and often require urgent specialist treatment. Chronic leukemias may be found incidentally on a blood count and can remain asymptomatic for a time. Age, subtype, cytogenetic and molecular findings, performance status and comorbidities strongly influence treatment planning. ^{[1] [2] [3]}

Symptoms and warning signs

Symptoms often reflect failure of normal marrow production. Anemia can cause fatigue, pallor and shortness of breath; low platelets can produce petechiae, bruising or bleeding; and dysfunctional or low normal white cells increase infection risk. Leukemic infiltration can cause bone pain, enlarged nodes, liver or spleen enlargement and, in selected subtypes, neurologic or skin findings. ^{[1] [2]}

Acute leukemia can present as an emergency. Fever in a patient with severe neutropenia, uncontrolled bleeding, symptomatic hyperleukocytosis, tumor lysis syndrome or severe anemia requires immediate hospital assessment. During treatment, even subtle fever or new respiratory symptoms can be important because immune defenses may be profoundly reduced. ^{[1] [2]}

Diagnosis

A complete blood count is often the first abnormal test, but a normal or modest white-cell count does not exclude leukemia. Peripheral smear review may reveal blasts or a clonal-looking lymphocyte population. Most suspected acute leukemias require urgent hematology evaluation and bone marrow sampling to establish lineage, percentage of abnormal cells and morphology. ^{[1] [2]}

Modern leukemia diagnosis combines morphology, immunophenotyping and genetic testing. Flow cytometry identifies lineage-associated cell markers. Cytogenetics, fluorescence in situ hybridization and molecular assays detect recurrent genomic changes that can determine the formal disease classification, prognosis, measurable residual disease strategy and eligibility for targeted agents. ^{[1] [2] [3]}

Reactive leukocytosis, severe infection, vitamin deficiencies, aplastic or myelodysplastic disorders, lymphoma with blood involvement and other marrow diseases can mimic parts of a leukemia presentation. Persistent unexplained cytopenias, blasts or striking blood-count abnormalities should not be attributed to infection or medication without appropriate evaluation. ^{[2] [3]}

Causes, risk factors and clinical context

Recognized risk factors and clinical contexts include Increasing age for many leukemia types, Prior chemotherapy or radiation for some secondary leukemias, Certain inherited cancer-predisposition syndromes, Benzene exposure for selected myeloid malignancies, Clonal hematopoietic or marrow disorders, and Subtype-specific genetic risk factors. Risk factors change pre-test probability but do not diagnose the condition by themselves; their importance depends on the individual patient and the rest of the clinical picture. ^{[1] [2]}

Acute leukemia progresses rapidly without effective treatment. Chronic leukemia has a more variable trajectory: some patients with CLL can be observed without immediate therapy, while CML is typically treated with continuous targeted tyrosine-kinase inhibition. Response is assessed not only by symptoms and blood counts but also by marrow and molecular measures when appropriate. ^{[1] [2] [3]}

Complications and why the diagnosis matters

Potential complications include Severe infection, Bleeding, Anemia and cardiopulmonary strain, Tumor lysis syndrome, Leukostasis in extreme leukocytosis, and Relapse or treatment-related toxicity. The practical reason to identify Leukemia accurately is to prevent avoidable morbidity, recognize people who need specialist or emergency care, and avoid therapies that could be ineffective or harmful for a different diagnosis. ^{[1] [2]}

Prognosis differs dramatically across leukemia types and molecular subgroups. Age, performance status, chromosome and gene findings, depth of response and measurable residual disease all matter. Population survival statistics cannot predict an individual outcome and should be interpreted within a specific subtype and treatment era. ^{[1] [2] [3]}

Treatment and management

Treatment is subtype-specific. Acute leukemias may require multi-drug induction and consolidation, targeted agents, immunotherapies and sometimes allogeneic stem-cell transplantation. CML is usually treated with BCR::ABL1-targeted tyrosine-kinase inhibitors. CLL treatment can include targeted oral agents or antibody-based regimens, while asymptomatic low-risk disease may be monitored until treatment criteria are met. ^{[1] [2]}

Supportive care is integral to leukemia treatment and may include red-cell or platelet transfusions, antimicrobial prophylaxis or treatment, management of nausea and mucositis, fertility counseling and prevention or treatment of tumor lysis. Vaccination and infection-prevention plans are individualized because immune function can be impaired by both disease and therapy. ^{[1] [2] [3]}

Leukemia therapy is specialist treatment with substantial interaction, organ-toxicity and infection considerations. Patients should not change targeted therapies, chemotherapy schedules or prophylactic medicines without their hematology team. Fever during periods of neutropenia is an emergency and should follow the treatment center’s urgent-contact plan. ^{[1] [2]}

Follow-up, recovery and prevention

Follow-up uses blood counts, clinical examination and disease-specific response measures. Acute leukemias may be monitored for measurable residual disease; CML uses serial BCR::ABL1 measurements; CLL monitoring depends on treatment and disease status. Survivorship care also addresses late effects, vaccination, secondary cancers and cardiovascular or endocrine consequences of therapy. ^{[1] [2]}

Most leukemia cannot be reliably prevented. Avoiding tobacco and unnecessary benzene exposure and using radiation or cytotoxic therapy only when medically justified may reduce some risk, but many cases occur without a modifiable cause. People with inherited predisposition or prior high-risk therapy may need specialized surveillance rather than population screening. ^{[1] [2] [3]}

Special situations and care pathway

Children have a different leukemia distribution from adults, with ALL especially important. Older adults may have more adverse-risk genetics and comorbidities that affect treatment intensity. Pregnancy during leukemia is rare and requires coordinated maternal-fetal and hematologic oncology care because disease urgency and fetal considerations must be balanced. ^{[1] [2] [3]}

Suspicious blood counts should prompt repeat confirmation and urgent hematology referral when blasts or severe cytopenias are present. Diagnosis, genetic profiling and treatment planning occur in specialist centers. Emergency departments manage acute infection, bleeding, leukostasis and metabolic complications in coordination with hematology. ^{[1] [2]}

When to seek urgent medical care

Seek urgent or emergency care for fever during known or suspected severe neutropenia, uncontrolled bleeding, rapidly worsening shortness of breath, new confusion, severe chest pain, fainting or a very abnormal blood count with acute symptoms. ^{[1] [2]}

Sources

1. National Cancer Institute (NIH) — Leukemia—Patient Version
2. National Cancer Institute (NIH) — Leukemia—Health Professional Version
3. MedlinePlus — Leukemia
4. National Heart, Lung, and Blood Institute (NIH) — Blood Tests

This article is based on trusted medical sources and is awaiting clinician review. It is not a substitute for personalized medical advice.